# **Special Issue**

# The Analysis of Circulating Tumor Cells (CTCs): New Insights into the Biology of Cancers

### Message from the Guest Editors

Tumor cells that allow the primary tumor to enter circulation and finally metastasize are known as circulating tumor cells (CTCs). CTCs have developed ways to survive in the hostile microenvironment of the bloodstream. More specifically, they can alter their genetic and phenotypic characteristics by expressing specific proteins, and hence create beneficial niches, acquire drug resistance, escape immune response, and enhance their invasive abilities. Phenotypic characterization of these cells could give useful information regarding prognosis, response to treatment, and early diagnosis. Moreover, the study of CTCs is not only instrumental as a basic research tool but also allows the serial monitoring of tumor genotypes and may therefore provide predictive and prognostic biomarkers for clinicians. This Special Issue of *Cancers* focuses on investigations regarding the biology and clinical relevance of circulating tumor cells, encompassing new research articles and timely reviews.

### **Guest Editors**

Prof. Dr. Vassilis Georgoulias

Dr. Galatea Kallergi

Dr. Athina N. Markou

### Deadline for manuscript submissions

closed (31 October 2024)



### Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/122410

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





## **Cancers**

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



## **About the Journal**

### Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

#### **Editor-in-Chief**

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

#### **Author Benefits**

### **Open Access:**

free for readers, with article processing charges (APC) paid by authors or their institutions.

### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

